Alzheimer’s disease accounts for over 60 percent of dementia cases. The greatest known risk factor for AD is aging, with most patients diagnosed at 65 or older. However, AD is not just a disease effecting this population. Approximately 200,000 Americans under the age of 65 have early-onset AD.
Our Clearway Global network is managing the development of a new chemical entity (NCE) that will treat symptoms of Alzheimer’s disease and eliminate side effects normally seen with all other medications that treat these growing number of patients.
We are also managing the international licensing opportunity for this new patented NCE.